Why Invest?

Cognetivity Neurosciences (CSE:CGN OTCQB:CGNSF), a medical technology company founded at the University of Cambridge, UK, has developed a five-minute cognitive function test, powered by artificial intelligence. Its Integrated Cognitive Assessment (ICA) is an easy-to-use, sensitive, reliable and hugely scalable test that represents a major advance in monitoring brain health.

Delivered via touchscreen devices and the web, the ICA provides a unique end-to-end solution for measuring cognition. It allows early detection of neurological issues, leading to better outcomes for patients and reduced costs for healthcare systems.

Cognetivity is commercialising the ICA in medical and corporate markets in the USA, Europe, the Middle East and elsewhere. With a global estimated market size for cognitive assessment and training expected to reach $11.4 billion by 2026, rising at a market growth of 26.6% CAG, and more than 350 million over 55s in USA, EU and Middle East, Cognetivity’s unique technology is poised to transform the way that brain health is measured and to generate substantial revenue in the coming years.

Our partners

We work with world-leading organisations, from global universities to leading research organisations.

Latest news and updates

In Vivo Logo

A blood pressure test for Dementia

News | No Comments
Neuroscience Innovator, Cognetivity Neurosciences, Looks At Early Diagnosis From New Angle "The attention accorded to…

BioSpace Global Roundup, July 25th

News | No Comments
A summary of Cognetivity’s recent work has been included in BioSpace’s weekly roundup up of…
TechWorld Logo

Cognetivity takes a radical new approach to dementia diagnosis

News | No Comments
Techworld spoke to the Cognetivity founder about developing a new tool for rapid dementia diagnosis

Looking to download our Investor Materials?

Please submit the following form

We’re looking forward to hearing from you.

Talk to a member of the team